TY - JOUR
T1 - Influence of HLA alleles on the rate of progression of vertically transmitted HIV infection in children
T2 - Association of several HLA-DR13 alleles with long-term survivorship and the potential association of HLA- A*2301 with rapid progression to AIDS
AU - Chen, Y.
AU - Winchester, R.
AU - Korber, B.
AU - Gagliano, J.
AU - Bryson, Y.
AU - Hutto, C.
AU - Martin, N.
AU - McSherry, G.
AU - Petru, A.
AU - Wara, D.
AU - Ammann, A.
N1 - Funding Information:
We thank Dr. Leslie Johnston-Dow, of the human genetic analysis group of the Applied Biosystems division of the Perkin-Elmer Corporation for providing HLA-A sequence-based typing kits, technical advice and pre-release versions of the HLA typing software. We are indebted to the entire staff of the Pediatric AIDS Foundation for greatly facilitating this effort, their sustained encouragement and for their many fruitful interactions. This work was supported by the NIH grant AR39626.
PY - 1997/7
Y1 - 1997/7
N2 - The influence of host immunogenetics on the outcome of vertically transmitted HIV infection in children was examined in a multicenter cross sectional study of long term survivors and rapid progressors. Sequence-based typing was performed for the DRB1, DQB1 and HLA-A loci. 36.7% of 30 children surviving more than 8 years had one or mote of the HLA-DR13 alleles, versus none of 14 rapidly progressing children who died within 2 years of age, p = 0.009, Haldane RR = 17.1. The alleles variably associated with this beneficial response to HIV were: DRB1*1301, DRB1*1302, DRB1*1303 and DRB1*1310, suggesting that the DR13 effect acted as a dominant trait. An additional 6 children were typed only by the SSOP method resulting in 44.4% of 36 long term surviving children with a DR13 allele and none of 14 rapid progressors, p = 0.002, Haldane RR = 23.3. No single DQB1 allele accounted for the HLA-DR13 allele association. In contrast, the presence of HLA A*2301 was associated with rapid progression to AIDS, 4% of long term survivors vs. 57.1% of 7 rapid progressors, p = 0.0006, RR = 0.031. Although the sample size is small, the marked differences in allele frequency along with differences between the peptide binding pockets of the HLA-A9 group of alleles including HLA A*2301 and the remainder of the HLA-A alleles suggest a structural basis for the dominant disadvantageous immune response to HIV conferred by A*2301.
AB - The influence of host immunogenetics on the outcome of vertically transmitted HIV infection in children was examined in a multicenter cross sectional study of long term survivors and rapid progressors. Sequence-based typing was performed for the DRB1, DQB1 and HLA-A loci. 36.7% of 30 children surviving more than 8 years had one or mote of the HLA-DR13 alleles, versus none of 14 rapidly progressing children who died within 2 years of age, p = 0.009, Haldane RR = 17.1. The alleles variably associated with this beneficial response to HIV were: DRB1*1301, DRB1*1302, DRB1*1303 and DRB1*1310, suggesting that the DR13 effect acted as a dominant trait. An additional 6 children were typed only by the SSOP method resulting in 44.4% of 36 long term surviving children with a DR13 allele and none of 14 rapid progressors, p = 0.002, Haldane RR = 23.3. No single DQB1 allele accounted for the HLA-DR13 allele association. In contrast, the presence of HLA A*2301 was associated with rapid progression to AIDS, 4% of long term survivors vs. 57.1% of 7 rapid progressors, p = 0.0006, RR = 0.031. Although the sample size is small, the marked differences in allele frequency along with differences between the peptide binding pockets of the HLA-A9 group of alleles including HLA A*2301 and the remainder of the HLA-A alleles suggest a structural basis for the dominant disadvantageous immune response to HIV conferred by A*2301.
UR - http://www.scopus.com/inward/record.url?scp=19244378625&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=19244378625&partnerID=8YFLogxK
U2 - 10.1016/S0198-8859(97)00092-X
DO - 10.1016/S0198-8859(97)00092-X
M3 - Article
C2 - 9361967
AN - SCOPUS:19244378625
SN - 0198-8859
VL - 55
SP - 154
EP - 162
JO - Human Immunology
JF - Human Immunology
IS - 2
ER -